Condition: B-cell Malignancies · Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B-cell Malignancies. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell Malignancies.
This description comes directly from the study's public registry record.
Sanbin Wang, PhD · +86 13187424131 · sanbin1011@163.com
Mengli Xu · +86 18771696856 · menglixu0318@163.com
Always discuss trial participation with your own doctor first.
| 920th HJointLogistics | Kunming, Yunnan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07065279